In vitro three-dimensional (3D) cultures are emerging as novel systems with which to study tissue development, organogenesis and stem cell behavior ex vivo. When grown in a 3D environment, embryonic stem cells (ESCs) self-organize into organoids and acquire the right tissue patterning to develop into several endoderm- and ectoderm-derived tissues, mimicking their in vivo counterparts. Tissue-resident adult stem cells (AdSCs) also form organoids when grown in 3D and can be propagated in vitro for long periods of time. In this Review, we discuss recent advances in the generation of pluripotent stem cell- and AdSC-derived organoids, highlighting their potential for enhancing our understanding of human development. We will also explore how this new culture system allows disease modeling and gene repair for a personalized regenerative medicine approach.
Modern biology has brought great progress in our understanding of how mammals develop from a single totipotent cell to a complex adult organism. For the past three decades it has been possible to derive embryonic stem cells (ESCs) from the epiblast and expand them continuously in vitro. More recently, induced pluripotent stem cells (iPSCs) can be generated from almost any mature cell type in our bodies. These breakthroughs have allowed the differentiation of various pluripotent stem cell (PSC) populations into somatic cell derivatives in vitro. Tissue-resident adult stem cells (AdSCs) have also gained much attention recently for their intrinsic abilities to self-renew and differentiate into the cell types present in adult tissues while retaining genomic stability. However, studying tissue patterning and organ morphogenesis in vitro has been hindered by the lack of appropriate culture systems that would allow the cell-cell interactions needed for organ formation. The recent development of three-dimensional (3D) culture systems has made it possible to recapitulate partially the complexity of mammalian organogenesis in vitro (Figs 1 and 2) and has also allowed the generation of transplantable tissues (Assawachananont et al., 2014). Culturing human derivatives (hESCs/hiPSCs/hAdSCs) in 3D has opened up new horizons for the exploration of human development and the development of regenerative medicine approaches.
In 1979, in a seminal paper titled ‘Stem Cell Concepts’, L. G. Lajtha produced the classical definition of a stem cell as a cell with self-renewal and multi-lineage potential – a definition to which we will adhere in this Review (Lajtha, 1979). This definition covers various PSCs (ESCs/iPSC) as well as some AdSCs and adult tissue progenitors. Culturing these different types of stem cells in 3D under appropriate culture conditions has resulted in the formation of structures that resemble an organ in culture and have been termed ‘organoids’. In this Review, we define ‘organoid’ as a 3D structure derived from either PSCs, neonatal tissue stem cells or AdSCs/adult progenitors, in which cells spontaneously self-organize into properly differentiated functional cell types and progenitors, and which resemble their in vivo counterpart and recapitulate at least some function of the organ. Thus, this definition encompasses 3D structures containing mainly epithelial derivatives and, sometimes, also a mesenchymal component. Here, we propose using the terms ‘PSC-derived’, ‘neonate-derived’ or ‘AdSC-derived’ to indicate the cell/tissue that gives rise to the organoid.
In this Review, we will focus on the recent advances in organoid cultures derived from PSCs and AdSCs. We will first explore PSC-derived organoids by focusing on stomach organoids. Then, we will discuss stomach, intestine, liver and pancreas organoids generated from adult or neonatal stem cells. We will then compare the genetic stability of PSC- and AdSC-derived organoids, and discuss their potential uses for understanding human development and modeling human disease. Finally, we will introduce the various emergent genetic engineering tools that hold potential for gene repair in stem cell cultures, with the ultimate aim of personalized regenerative medicine.
Organoids derived from PSCs
In mouse, ESCs can be derived from the inner cell mass (ICM) of 4-day-old blastocysts and cultured on feeder layers (Evans and Kaufman, 1981; Martin, 1981). When injected into blastocysts, ESCs contribute to all germ layers (Bradley et al., 1984), thus indicating pluripotency. Similarly, hESCs have been isolated from human blastocysts prior to implantation (Thomson et al., 1998). Additionally, somatic cells can be reprogrammed to a pluripotent state by cell fusion (Blau et al., 1983), nuclear transfer (Chung et al., 2014; Gurdon, 1962; Tachibana et al., 2013) or by the overexpression of pluripotent factors (Takahashi and Yamanaka, 2006), providing another source of PSCs in vitro. All these pluripotent cells have made it possible to generate almost all human and mouse cell types in vitro. Despite this great achievement, in vitro differentiation protocols in 2D do not recapitulate organ morphogenesis. In this regard, the conversion of culture systems from 2D to 3D has recently allowed the development of organoids to model tissues of ectoderm [retinal (Eiraku et al., 2011; Kuwahara et al., 2015; Nakano et al., 2012), pituitary (Suga et al., 2011), cerebral organoids (Lancaster et al., 2013; Muguruma et al., 2015), inner ear (Koehler et al., 2013)], endoderm [small intestine (Spence et al., 2011), thyroid (Antonica et al., 2012), liver (Takebe et al., 2013), stomach (McCracken et al., 2014) and lung (Dye et al., 2015)] and mesoderm [cardiac muscle (Stevens et al., 2009)]. Retinal (optic cup), cerebral, pituitary and small intestinal organoid cultures have been excellently reviewed elsewhere (Howell and Wells, 2011; Lancaster and Knoblich, 2014; Sasai, 2013; Sasai et al., 2012; Wells and Spence, 2014) (Fig. 1 and Table 1). Therefore, below, we will use human ESC-derived gastric organoid cultures as an example of endodermal organ formation from PSCs in vitro.
During mouse embryonic development, the definitive endoderm (DE), which requires Nodal signaling for its specification (Zorn and Wells, 2009), gives rise to the foregut. Around embryonic day E9.5-10, the stomach arises from the foregut as a very poorly differentiated epithelium that will undergo extensive remodeling during development (Zorn and Wells, 2009). Stomach specification requires transient inhibition of Wnt signaling mediated by sFRP1 and sFRP2 (Kim et al., 2005) and expression of mesenchymal FGF (Nyeng et al., 2007). Terminal cellular fates are induced before the glands are fully formed, between E15.5 and E16.5 (Nyeng et al., 2007). Then, the later action of epithelial Shh (Ramalho-Santos et al., 2000) and mesenchymal Bmp4 (Fukuda and Yasugi, 2005) will facilitate the further gland maturation, which will terminate during post-natal life (Fig. 3A).
The mature stomach is anatomically divided into two distinct areas: the corpus (main body of the stomach) and the pyloric antrum (close to the intestine). The epithelium comprises tubular-shaped invaginations into the lamina propria known as gastric units, which are in turn divided into two parts: the pit and the gland (Lee et al., 1982) (Fig. 3A). Whereas the corpus gastric units are responsible for the digestive functions of the stomach (acid and pepsinogen secretion), the pyloric-antrum units mainly produce mucus and enteroendocrine hormones (Karam and Leblond, 1993a; Vries et al., 2010).
By exploiting our knowledge of anterior endoderm patterning and stomach development, gastric tissue has been obtained through the directed differentiation of human ESC or human iPSCs in vitro (McCracken et al., 2014). As a first step towards formation of human gastric organoids (hGOs), hESC or hiPSCs were differentiated into DE using Activin, which mimics endogenous Nodal signaling (D'Amour et al., 2005; Kubo et al., 2004), followed by Wnt, FGF4 and noggin (NOG) treatment. NOG is essential to prevent intestinalization and to promote a foregut fate (McCracken et al., 2014). Then, after the DE was exposed to RA in the presence of 3D extracellular matrix (Matrigel) to induce antrum specification, these foregut organoids were maintained in an EGF-rich medium to generate gastric organoids containing all cell types present in the stomach antrum (McCracken et al., 2014) (Fig. 3B). Because these cultures were specified into antrum instead of corpus, they did not generate acid-producing cells. This is remarkable, as it indicates that the system fully recapitulates antrum development and morphogenesis in vitro. Of note, mouse PSC-derived corpus cultures that generate functional parietal cells in vitro have just recently been achieved (Noguchi et al., 2015). This, again, suggests that culturing hESCs in a 3D environment, combined with our current knowledge on embryonic stomach development, has been instrumental in successfully developing stomach organoids, which will facilitate the study of human stomach development ex vivo from embryonic development to postnatal growth.
Organoids derived from adult stem cells
Experiments performed on skin by Barrandon and Green in the late 1980s proved that epidermal stem cells were expandable and could generate vast amounts of epithelium in vitro, when supported by lethally irradiated 3T3 cells (Barrandon and Green, 1987). However, expanding stem/progenitor cells from other adult tissues proved to be difficult and for decades, keratinocyte cultures remained the sole example of primary adult stem cell cultures. Recently, the combination of ECM and 3D culture systems with a deeper knowledge of the signaling pathways important for AdSC maintenance and tissue repair have been instrumental for the development of primary AdSCs cultures. Thus, mammary gland (Dontu et al., 2003), bone (Kale et al., 2000), small intestine (Ootani et al., 2009; Sato et al., 2009), stomach (Barker et al., 2010b; Bartfeld et al., 2015; Li et al., 2014; Stange et al., 2013), colon (Jung et al., 2011; Li et al., 2014; Sato et al., 2011), liver (Huch et al., 2013b, 2015), pancreas (Boj et al., 2015; Huch et al., 2013a), lung (Lee et al., 2014), prostate (Gao et al., 2014; Karthaus et al., 2014; Xin et al., 2007), salivary gland (Nanduri et al., 2014) and tongue (Hisha et al., 2013) organoids have all been derived in vitro from AdSCs (Fig. 2 and Table 1). In this section, we will focus on the development of organoids derived from adult stem/progenitor cells, paying special attention to stomach, intestine, liver and pancreas cultures.
Organoid cultures from high turnover organs: stomach and gut organoids
A recent series of studies has demonstrated that the maintenance and repair of adult tissues with high cellular turnover relies on small populations of actively cycling tissue resident stem cells. A variety of techniques, ranging from 3H-thymidine labeling to Cre-reporter lineage tracing, applied to the stomach and intestine, allowed AdSCs to be identified at the very bottom of the invaginations of the mucosa into the submucosa, in the crypt of Lieberkühn (intestine) and gland bottom (stomach) [reviewed by Barker et al. (2010a)].
In the stomach, classical electron microscopy and 3H-thymidine radio-autography revealed the existence of undifferentiated cells in the isthmus of the gastric units, which were proposed as the stem cells of the stomach responsible for the rapid homeostatic turnover of the epithelium (Karam and Leblond, 1993). However, in 2010, lineage tracing experiments showed that cells expressing the Wnt target gene Lgr5, found at the bottom of the antro-pyloric gland, were bona fide mouse stomach stem cells and would contribute to the normal homeostasis of the pyloric epithelium during the entire lifespan of a mouse (Barker et al., 2010b). Although these results have challenged the previous view that stomach stem cells resided in the isthmus region of the stomach gland (Karam and Leblond, 1993), they do not conclusively disprove the existence of a – yet to be identified – isthmus stem cell. In this regard, it was shown that upon IFNγ stimulation, a rare population of Villin+ isthmus cells function as stomach stem cells (Qiao et al., 2007).
The identification of Lgr5+ pyloric stem cells led to the development of an in vitro 3D organoid culture system (Barker et al., 2010b). Pioneering work from Ootani et al. had previously shown that stomach tissue could be maintained for some days in an air-liquid interphase 3D culture system (Ootani et al., 2000). Based on this work, the first long-term culture of mouse gastric stem cells from corpus and pylorus was achieved using Matrigel as 3D basal ECM and a cocktail of growth factors important for stomach stem cell maintenance and/or stomach development (Barker et al., 2010b; Stange et al., 2013) (Fig. 3C). The cocktail of growth factors included: (1) high Wnt signaling by combining Wnt3a ligand and Rspo1 (Carmon et al., 2012; de Lau et al., 2011), (2) the mitogens EGF and FGF10 (Nyeng et al., 2007), and (3) the Bmp antagonist NOG to prevent the posteriorization and differentiation of the culture. Similar culture conditions combined with a blockade of TGFβ signaling have allowed the long-term expansion of human gastric stomach stem cells into 3D organoids that display characteristics of the adult stomach epithelium (Bartfeld et al., 2015) (Fig. 3C).
A shortcoming of these cultures was the lack of parietal cell differentiation in the corpus-derived organoids. One potential explanation for this could be the lack of epithelial-mesenchymal interactions, as organoids exclusively form the epithelial component of the stomach tissue. In line with this, some parietal differentiation was observed when neonatal stomach epithelium was cultured in combination with its mesenchymal niche (Li et al., 2014) or when gastric corpus organoids were co-cultured with immortalized stomach mesenchymal cells (Schumacher et al., 2015). One advantage of AdSC-derived gastric organoids over human PSC-derived ones is that they allow the expansion of adult tissue stem cells as well as adult cancer stem cells. Indeed, gastric tumors derived from patient biopsies can be expanded in culture (Bartfeld et al., 2015). Therefore, AdSC-gastric cultures could potentially be used for cancer drug testing and personalized medicine for those patients which biopsies could be expanded and tested in culture.
In the intestine, the signaling pathways involved in the maintenance of the tissue include Wnt, Notch, FGF/EGF and Bmp/Nodal [for details refer to Sato and Clevers (2013)], with Wnt being crucial for maintaining and driving the proliferation of the stem cell pool (Korinek et al., 1998; Sato and Clevers, 2013). Small intestinal crypt-base columnar (CBC) cells, marked by Lgr5, Olfm4, CD133, Lrig1 or Tnfsrf19, among others, have been proven to be bona fide stem cells by extensive genetic lineage tracing analysis (Barker et al., 2007; Snippert et al., 2009; Stange et al., 2013; van der Flier et al., 2009; Wong et al., 2012). CBC cells persist during the entire mouse lifespan, and their progeny includes all differentiated cell lineages of the epithelium [for details refer to Barker et al. (2010a)]. Upon tissue damage, label-retaining Lgr5+ cells (Buczacki et al., 2013) and Dll1+ cells (van Es et al., 2012), both precursors of the secretory lineage, can function as ‘reserve’ stem cells. Along the same lines, non-Lgr5+ cells marked by Bmi1 (Sangiorgi and Capecchi, 2008; Tian et al., 2011; Powell et al., 2012) or Hopx (Takeda et al., 2011) were shown to behave as intestinal stem cells upon loss of the CBC compartment.
By combining a 3D culture system and the knowledge of the signaling pathways at play in the intestinal stem cell niche, a 3D in vitro culture system to grow intestinal epithelial organoids from intestinal epithelium (Ootani et al., 2009) or from a single adult Lgr5+ CBC intestinal cell (Sato et al., 2009) was developed. Intestinal organoids grown in Matrigel in a medium supplemented with EGF, NOG and the Wnt agonist Rspondin (Rspo) were shown to expand long term in culture while retaining their ability to generate the different intestinal epithelial cells (Ootani et al., 2009; Sato et al., 2009) (Fig. 4A). Furthermore, these organoids were expanded for over a year in vitro, far beyond the Hayflick limit (Hayflick, 1965), which predicts that primary non-transformed cells only divide 40-60 times (∼2-3 months) before undergoing senescence. Of note, intestinal organoids have also been generated from the above-mentioned non-CBC cells by culturing them in a Wnt3a-supplemented medium (van Es et al., 2012). Similarly, mouse- and human-derived colonic stem cells could also be expanded in culture with a minor modification to the culture medium composition (Jung et al., 2011; Sato et al., 2011). For more extensive details, intestinal organoids have been elegantly reviewed elsewhere (Sasai et al., 2012; Sato and Clevers, 2013; Wells and Spence, 2014).
Organoid cultures from organs with slow physiological turnover: liver and pancreas
During embryonic development, the liver and pancreas develop from the same pool of progenitors (Deutsch et al., 2001). The two embryonic tissues express similar sets of transcription factors and are exposed to similar signaling pathways. These include FGF, HGF, Wnt, Bmp, RA and TGFβ, which promote proliferation, migration and survival of the respective progenitor pools [for details refer to Zaret and Grompe (2008); Zorn and Wells (2009)]. This knowledge has been exploited to produce embryonic liver- and pancreas-like cells from ESCs and iPSCs in vitro. Despite this groundbreaking work, primary adult liver and pancreas cells have proven difficult to expand in culture for long periods of time. Such cultures could facilitate the study of liver and pancreas function both during homeostasis and disease, and increase our understanding of the mechanisms to activate their proliferation during damage response. In the following section, we will discuss new advances in obtaining both mouse and human liver and pancreas organoid cultures and their uses for human disease modeling and regenerative medicine.
The adult liver is mainly composed of hepatocytes and ductal cells that work in conjunction with endothelial and mesenchymal cells. Both hepatocytes and ductal cells derive from hepatoblasts, the endodermal fetal liver progenitor cell. The characteristics of hepatoblasts, and protocols for their isolation and culture, have been recently reviewed elsewhere (Miyajima et al., 2014) and, therefore, will not be detailed here. Whereas hepatoblasts generate hepatocytes and ductal cells during development, in normal adult homeostasis, the liver is mostly maintained by the self-replication of existing adult mature hepatocytes and ductal cells. Indeed, extensive lineage tracing approaches indicate that the contribution of progenitor cells to the normal homeostasis is negligible, at least in mouse models (Carpentier et al., 2011; Schaub et al., 2014; Tarlow et al., 2014; Yanger et al., 2014). However, in vitro and upon transplant, mouse ductal cells (Dorrell et al., 2014; Tarlow et al., 2014) and human EpCAM+ ductal cells (Cardinale et al., 2011; Huch et al., 2015; Schmelzer et al., 2007) display characteristics of liver progenitors (i.e. self-renewal and bi-potency) as shown by clonogenic and differentiation assays (Dorrell et al., 2014; Tarlow et al., 2014; Cardinale et al., 2011; Huch et al., 2015; Schmelzer et al., 2007).
Following damage, the adult liver excels in terms of its regenerative capacity. There is a clear consensus that, upon hepatectomy, adult ductal cells and hepatocytes proliferate to generate ductal cells and hepatocytes, respectively [reviewed by Michalopoulos (2014)]. However, the identification of the cells responsible for liver regeneration following toxic damage is an area of extensive investigation. Recent reports using viral-mediated Cre lineage tracing approaches, indicate that hepatocytes are the major player that contributes to the repair of the damaged liver (Schaub et al., 2014; Yanger et al., 2014), whereas other studies found that the ductal population can act as a bi-potent progenitor population that would also contribute to liver regeneration (generating hepatocytes and duct cells) but to a lesser extent (Dorrell et al., 2011; Español-Suñer et al., 2012; Furuyama et al., 2011; Huch et al., 2013b; Shin et al., 2011), or under extensive damage to the hepatocyte compartment (Lu et al., 2015). Interestingly, this bi-potent ductal population, either from a damaged or an undamaged liver, turned out to be a source for adult liver organoid culture (Dorrell et al., 2014; Huch et al., 2013b, 2015). Here, we will focus on the establishment of organoid cultures from cells which, at least in vitro, fulfil the stem cell criteria as defined by Lahtja; self-renew and differentiate (as described above), and which were found to have a greater potential in expansion in vitro over mature hepatocytes.
Several signaling pathways have been involved in the repair of the liver after damage. Indeed, Wnt (Boulter et al., 2012; Monga et al., 2001), HGF (Matsumoto and Nakamura, 1991) and FGF (Takase et al., 2013) are essential for liver regeneration. Despite this knowledge, the expansion of adult primary liver cells in vitro has remained a challenge. Pioneering work from Michalopoulos et al. showed that primary liver cells cultured in 3D could be maintained in culture in the presence of EGF, HGF and the corticoid Dexamethasone (Michalopoulos et al., 2001). However, these conditions did not allow the long-term expansion of liver progenitors. A 3D in vitro culture system for the long-term expansion of adult liver cells was recently developed by combining Matrigel with HGF, EGF and factors induced during liver damage [FGF (Takase et al., 2013) and Rspo1, produced during liver regeneration following CCl4 damage (Huch et al., 2013b)] (Fig. 4B). Of note, both damage-induced progenitors and healthy adult mouse liver tissue can be expanded under these culture conditions (Huch et al., 2013b). Typically, the expanded cells self-organize into 3D structures that have a ductal (Krt19+) single-layered epithelium compartment and a pseudo-stratified compartment that express both ductal (Krt7, Krt19) and hepatocyte (Ttr, Hnf4a) markers.
The cellular expansion potential is remarkable, as 106 cells can be readily generated in ∼5-6 weeks from a single cell. By supplementing the medium with additional factors, it was recently reported that EpCAM+ single adult human liver cells can be expanded long-term (>5 months) in vitro and generate 3D organoid cultures (Huch et al., 2015). Addition of an activator of cAMP signaling and inhibition of TGFβ signaling was crucial to achieve the remarkable longevity of this organoid culture. Of note, only human adult liver tissue, but not mouse, requires inhibition of TGFβ signaling for long-term expansion of organoids. This is a recurrent and very intriguing observation: so far, for all human AdSC-derived organoid cultures developed – colon (Sato et al., 2011), stomach (Bartfeld et al., 2015) and liver (Huch et al., 2015) – the inhibition of the TGFβ pathway is necessary in order to sustain long-term growth. The reason as to why the human cells are sensitive to TGFβ signaling, whereas mouse cells are not, is unknown. Further studies will be required to answer this.
In mouse and human liver organoid cultures, blockade of the alternative ductal fate by Notch inhibition (McCright et al., 2002), and Wnt-mediated proliferation in combination with the addition of Dexamethasone and Bmp, facilitated hepatocyte differentiation from organoids (Huch et al., 2013b, 2015) (Fig. 4B). Differentiated cells displayed characteristics of functional hepatocytes in vitro and prolonged the life-span of liver-damaged animals upon transplantation (Huch et al., 2013b). Are we then already ready to start cell therapy transplantations? Probably not yet. It is worth noting that in mouse-to-mouse transplants only 25% of the animals displayed detectable engraftment (Huch et al., 2013b). The reasons for this could range from the fact that only 33% of the cells to be transplanted acquire a hepatocyte fate, to the lack of an intrinsic ability of the expanded mouse cells to differentiate and proliferate in the host tissue. Unfortunately, the nature of the mouse model used in the human-to-mouse transplantation study precluded the analysis of the human cells' functionality in vivo (the non-transplanted mice did not display any signs of liver failure). Further optimization of hepatocyte differentiation and transplantation efficiency will be necessary in order to consider therapeutic liver organoid transplants to humans.
One factor to consider when using AdSC-derived liver organoids to study liver development is that they only expand and differentiate into the epithelial derivatives of the liver (hepatocytes and duct cells). However, previous studies have described that reciprocal tissue interactions between the embryonic endoderm and the nearby mesoderm are required for liver organogenesis (Zorn, 2008) and, so far, AdSC-derived liver organoids do not allow the study of such complex interactions. Recently, an elegant attempt at generating a complete developing liver organ with mesodermal and endodermal components in vitro was made by mixing human iPSC-derived hepatocytes with mesenchymal stem cells (MSC) and umbilical cord cells (HUVECS) in a 3D culture system. This gave rise to embryonic liver bud organoids formed by proliferating hepatoblasts and other supporting cells that recapitulate aspects of liver embryonic organogenesis in vitro (Takebe et al., 2013). When ectopically transplanted into organs such as the mesentery or the brain, these organ buds developed into hepatic tissue exhibiting features of adult liver function. However, further optimization of the protocol is needed to complete a proper hepatic ductal network. Whether such a system can be generated using adult mouse or human liver progenitors in combination with endothelial and/or mesenchymal liver cells is still to be determined.
Finally, an interesting characteristic of AdSC-derived organoids is that they can be expanded long term from one single cell (clonal expansion). This enables the required depth of sequencing to perform studies on the genetic stability of adult stem cells/organoids by using whole-genome sequencing (WGS) (Behjati et al., 2014; Huch et al., 2015). Only one synonymous base substitution was identified in AdSC-derived human liver organoids expanded for more than 3 months from one single cell (Huch et al., 2015), suggesting a high genomic stability. This contrasts with iPSCs or ESCs, which, upon long-term expansion in an undifferentiated state (2D-culture), can exhibit aneuploidy and chromosomal alterations [reviewed by Liang and Zhang (2013)]. Thus, it seems that AdSC cultured in 3D preserve their genomic integrity. However, more studies will be required to assess whether this is a generalizable attribute of AdSC-derived organoids. Whether this would also apply to ESCs/iPSCs after transferring them to 3D-system for the generation of organoid structures is still to be determined.
Although the liver is capable of extensive de novo tissue formation after damage, the ability of the pancreas to regenerate is limited [reviewed by Zaret and Grompe (2008)], and embryonic and/or adult pancreas cells have proven difficult to maintain in culture. Recently, Anne Grapin-Botton and colleagues elegantly showed that with a 3D Matrigel-based system, mouse embryonic pancreas progenitors could be cultured in vitro. The system neatly recapitulates pancreas development and demonstrates exocrine (acinar) and endocrine (insulin+) cell differentiation in vitro. Interestingly, the authors observed that the use of 3D ECM-based Matrigel promoted the expansion of the embryonic progenitor pool (Greggio et al., 2013), arguing once more in favor of the importance of 3D systems to recapitulate ex vivo the interactions that occur in physiological conditions. Although this very elegant system allows pancreas development to be studied ex vivo, it does not support the long-term expansion of pancreas cells. To address this, 3D adult mouse pancreas cultures were established using similar culture conditions as those used for the liver and small intestinal organoids. Unlike liver cultures, noggin is required for the culture of pancreas organoids, in agreement with pancreas development (Wandzioch and Zaret, 2009). Thus, adult pancreas organoid cultures can be expanded long-term in 3D Matrigel in the presence of FGF10, Nog, Rspo1 and EGF (Huch et al., 2013a) (Fig. 4C). The resulting organoid structures are entirely composed of ductal cells that express the embryonic progenitor marker Pdx1 (Ahlgren et al., 1996). So far, differentiation of these cells into endocrine lineages in vitro has been unsuccessful. A potential reason could be that, in contrast to their embryonic counterparts, adult ductal cells have lost their bi-potency with regard to endocrine differentiation. However, it has been shown that adult ductal cells can revert to their embryonic state and re-activate the endocrine program (Sancho et al., 2014; Xu et al., 2008). Consistent with this, when the adult duct-derived organoid cells were mixed with embryonic pancreas and immediately transplanted into the kidney capsule, a high percentage of the cells differentiated into fully mature, mono-hormonal cells (insulin+, glucagon+ or somatostatin+) (Huch et al., 2013a). Other reasons could also account for the lack of differentiation observed from adult organoids in vitro, ranging from deficiencies in the culture components (e.g. growth factors and ECMs), to the lack of stromal or other supporting cells (e.g. endothelial cells). In fact, it has been shown that endothelial cues facilitate embryonic endocrine differentiation (Lammert et al., 2001). Thus, further studies are needed to address this lack of endocrine differentiation in vitro.
Organoid cultures: uses and applications
Unveiling developmental processes with human organoid cultures
An interesting feature of AdSC-derived organoid cultures is that they preserve their tissue identity. PSC-derived cultures are generated by the manipulation of medium conditions, which results in the acquisition of different cell fates. By contrast, AdSC-derived organoid cultures cannot be pushed to differentiate into other tissue types by simply changing the external factors. Changing tissue identity in these systems requires genetic manipulation. In this regard, only the loss of the master regulator Cdx2 can impose a stomach fate in adult intestinal organoid cultures (Simmini et al., 2014). Thus, in homeostatic adult tissue, trans-differentiation between different tissue types seems unlikely to occur spontaneously or by simple environmental changes, and tissues seem resistant to lineage changes. This is in clear contrast to what is observed in hPSCs-derived small intestine and stomach cultures, in which a change in BMP signaling at the pre-specification stage results in specification of stomach versus intestinal fate (McCracken et al., 2014). It is reasonable to speculate that the genetic/epigenetic programs that establish tissue identity become fixed at some point in the path from embryonic development to adult organ formation. Human organoid cultures have the potential to allow the identification of these regulatory mechanisms.
Modeling human disease using organoid stem cell cultures derived from patients
The establishment of adult human cultures directly from patients with rare genetic diseases has the potential to identify the mechanisms underlying such diseases and hence participate to the identification of treatments (Table 1). For example, the analysis of small-intestinal organoids from a patient with multiple intestinal atresia (a rare genetic disease that causes bowel obstruction) showed that this disease arises from a defect in the apicobasal polarity of the epithelium, which can be reverted by inhibiting Rho kinase (Bigorgne et al., 2014). Similarly, intestinal organoids derived from cystic fibrosis patients (a genetic disorder caused by mutations on the CFTR gene, encoding a chloride and thiocyanate ion channel) represent a fantastic platform to assay experimental treatments, as CFTR channel functionality is easy to assess in vitro (Dekkers et al., 2013).
In addition to diseases of the intestine, liver genetic diseases will also benefit from the possibility of culturing primary liver tissue from patients bearing pathogenic genetic mutations. In support of this concept, direct liver biopsies from patients with two rare liver disorders [Alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency, A1AT-D) and Alagille syndrome] were used to generate 3D organoids that partially phenocopied the corresponding disease (Huch et al., 2015). A1AT-D is caused by specific mutations of the A1AT gene. However, the development of the disease is highly variable between patients: some present severe symptoms and develop liver cancer, whereas others hardly develop any symptoms (Fairbanks and Tavill, 2008). This difference in the presentation of the pathology could be due to passenger mutations that can now be identified by deriving organoids directly from the diseased tissue.
In addition to their use for the study of human development and human monogenic diseases, human organoids could have a prominent role in enhancing our understanding of human cancer. Indeed, human primary prostate cancer- (Gao et al., 2014), stomach cancer- (Bartfeld et al., 2015), pancreas cancer- (Boj et al., 2015) and colon cancer- (van de Wetering et al., 2015) derived organoids have been expanded in vitro and observed to retain the heterogeneity of genetic alterations present in patient samples. The mechanism by which this heterogeneity is retained will require further investigation.
Genetic engineering in human ESC/iPSC and organoid cultures
The genetic stability of the organoid cultures, combined with their ability to phenocopy human diseases closely in vitro, and the emergence of novel genetic engineering tools to manipulate the human genome, open up incredible opportunities to obtain molecular insights into human development and disease. Here, we will discuss novel methods of genetic engineering and their application to stem cell cultures for gene correction of human monogenic disorders. Homologous recombination (HR) has been actively employed in mouse ESCs, starting with the monumental work of Mario R. Capecchi, who showed the high rate of HR events in mouse ESCs (Thomas and Capecchi, 1987). This method allowed for the selective modification of the mouse genome and thus the generation of gene-modified mutant mice, which contributed immensely toward the understanding of mammalian gene function. In addition, HR-mediated gene targeting will potentially enable the editing of our own genetic code to cure monogenic disorders or to eradicate viruses integrated into our genome. Much effort towards establishing this technology in human cells has therefore been deployed. However, unlike mouse ESCs, the frequency of HR events in human PSCs is extremely low. In the following sections, we will detail recent genetic tools developed to overcome HR inefficiency in hPSCs and human organoids.
Zinc-finger endonuclease-mediated genome editing in pluripotent stem cells
A hint on how to solve HR inefficiency in hPSCs came from the initial studies describing the mechanism of HR: a double-strand break (DSB) triggers HR-mediated DNA repair. In fact, DSBs enhance HR efficiency by two to three orders of magnitude in mouse 3T3 cells (Rouet et al., 1994). However, generating a DSB at a desired site in the genome presented an insurmountable problem until the introduction of programmable zinc-finger nucleases (ZFNs). ZFNs are composed of two domains: DNA-binding zinc-fingers and a FokI restriction endonuclease. DNA-targeting specificity is determined by the composition of the zinc-fingers. Using a pair of ZFNs, it became feasible to generate a DSB at a targeted DNA sequence with 18-24 bps of specificity, which greatly enhanced efficient gene targeting in human cells (Porteus and Baltimore, 2003). Subsequently, ZFN technology was rapidly adopted to generate desired mutations in many different cell types, including primary human T cells (Urnov et al., 2005), human stem cells (Lombardo et al., 2007), human ESCs and iPSCs (Hockemeyer et al., 2009; Zou et al., 2009).
Starting from the initial success of applying ZFNs to human genome editing, a number of groups reported and demonstrated the versatility of ZFNs for targeted gene correction in human stem cells, by demonstrating functional gene repair for A1AT-D (Yusa et al., 2011), sickle-cell anemia (β-globin) (Sebastiano et al., 2011; Zou et al., 2011) and Parkinson's disease (α-synuclein) (Soldner et al., 2011). In particular, Yusa et al. achieved several key milestones: the efficient gene correction of human iPSCs, the use of a PiggyBac selection cassette to achieve the clean correction of a point mutation without leaving any foreign DNA sequence, and the subsequent production of liver cells from the modified iPSCs. This work demonstrated a nearly complete cycle for autologous cell-based therapy – human iPSC generation from patient somatic cells, clean gene correction at the clinical level and, finally, target cell differentiation and production. However, there are still several technical problems to solve before we can use this new technology in a clinical context as a general medical practice. First, designing a functional pair of ZFNs is very challenging and the success rate is relatively low (20-25%). Second, the major steps involved in autologous cell therapy are still under development or need further optimisation. For example, the gene-free or vector-free reprogramming of human somatic cells to iPSCs is under investigation in order to achieve the highest efficiency without inducing any genetic errors. Another significant challenge lies in establishing the protocols to differentiate all the required somatic cell types. Recent advances in genome-editing methods (e.g. TALEN and CRISPR/Cas9) and 3D adult stem cell organoid culture techniques provide alternative choices for successful disease gene correction in autologous cell sources.
Novel programmable endonucleases – TALENs and CRISPR/Cas9 – for genome editing and 3D organoid cultures
Two types of programmable endonucleases have become a popular option for genome editing. Both originate from prokaryotes: TALEN, the first to be introduced in the field, comes from Xanthomonas, and CRISPR/Cas9 from Streptococcus. A TALEN DNA-binding finger recognizes one nucleotide of DNA. Thus, sequentially assembled TALEN-fingers are highly modular, simplifying the design step and greatly improving the success rate of gene targeting. CRISPR/Cas9 is composed of a guide RNA (gRNA) template and the Cas9 endonuclease. The specificity of the CRISPR/Cas9 system is determined by the gRNA. Owing to the simplicity of gRNA sequence modification, targeting Cas9 to different genes has become a routine practice in labs. These new genome-editing tools, of which respective advantages and drawbacks are listed in Table 2, have widened the choice and improved the feasibility of HR-mediated gene targeting. Two groups have elegantly used these new genome-editing tools in hPSCs for gene modification, inducible genome editing and multiplexing (Ding et al., 2013; González et al., 2014).
Three-dimensional adult stem cell organoid cultures represent the other innovation that facilitates autologous cell therapy. As detailed above, an appropriate growth factor cocktail with a 3D basement matrix allows the generation and long-term culture of human organoids from diverse tissues. Their remarkable longevity, genetic stability and ability to be implanted in vivo make them a suitable platform for gene correction of monogenic disorders. A proof-of-concept was reported in colonic organoids from cystic fibrosis (CF) patients (Dekkers et al., 2013), in which the CRISPR/Cas9 system was used to correct the F508 mutation. When combined with a targeting vector encoding the correct sequence, the DSB generated by CRISPR/Cas9 on the mutant sequence facilitated the HR-mediated integration of the targeting vector, thus reverting the F508 mutation back to wild type and restoring CFTR chloride channel function (Schwank et al., 2013). This approach – organoid establishment, genome engineering and transplantation (Fig. 5) – represents a novel, short cycle of autologous cell therapy for monogenic diseases that bypasses challenging biotechnological processes, such as error-free reprogramming and iPSC differentiation into highly pure and stable target cell types, apart from the inevitable genome engineering step. Taken together, all these innovative tools and technologies represent a huge advance towards the clinical application of organoids to regenerative medicine.
The recent development of 3D stem cell-derived culture systems has allowed the generation and the long-term expansion of adult tissues far beyond the predicted limit. Transferring this technology to the human arena has facilitated the generation of primary tissues from patients, thus opening the possibility of studying the molecular mechanisms involved in certain diseases. The parallel development of powerful genetic engineering tools to manipulate human genomes has opened the avenue for the manipulation of stem cells in vitro, which, when combined with 3D culture systems, might facilitate not only gene correction for regenerative medicine purposes but also the delineation of gene function during human development and disease. As we have discussed in this Review, these achievements would not have been possible without a thorough understanding of the signaling pathways important for organ development, organ growth and adult tissue maintenance and repair. Because this is an emerging field, it seems important to define clearly the terms and concepts that should be used moving forward. Hence, in this Review, we defined organoid as a 3D structure which should harbor cells with differentiation potential and organ functionality, and suggested using the nomenclature of ‘PSC-derived’, ‘neonate-derived‘ or ‘AdSC-derived’ organoid cultures to specify the cell type from which the organoid originates.
The era of 3D organ stem cell culture is just emerging. Thus, many questions remain to be answered. Whereas hints of how to address some short-term questions in the field have been suggested in this article, more challenging long-term questions are exposed below. For example, can these cultures complete our knowledge of what happens during embryonic development, postnatal growth and adult organ formation? We have discussed the example of the human stomach organoids in which the development of a full organ can be achieved in vitro from ESCs, by manipulating the medium composition or from the adult stomach stem cells contained in human biopsies. Therefore, it seems plausible that the combination of the two systems might help bridging the gap between our knowledge of development and that of organ maintenance in the adult. Unveiling those steps of human development and growth has been impossible until now, and organoid cultures have the potential to allow the easy identification of the regulatory networks involved in such processes. This should also hold true for other tissues from which organoid cultures can be obtained but await further development.
Another outstanding question relates to the robust genetic stability displayed by some AdSC-derived organoids. We have discussed that long-term organoid cultures from mouse small intestine (Behjati et al., 2014) and human liver (Huch et al., 2015) have shown that the cells accumulate very few base pair substitutions after months in culture while actively proliferating. Is this some intrinsic property of these cells or can it be generalized to other 3D AdSC cultures? Are the DNA repair pathways similar between different AdSC cultures? And does this hold true for PSC-derived organoid cultures? It is now well established that ESCs and iPSCs expanded in 2D-culture can suffer from genetic instability (Liang and Zhang, 2013). What are the intrinsic differences with AdSC cultures that would allow them to remain genetically stable?
Linked to the previous question, can we generate AdSCs from ESCs? So far, for intestine and stomach, both PSC-derived and AdSC-derived organoids have been obtained (Barker et al., 2010b; Bartfeld et al., 2015; McCracken et al., 2014; Sato et al., 2009; Spence et al., 2011). It has not been demonstrated yet whether adult tissue-specific stem cells could be isolated from PSC-derived organoids and propagated in culture as AdSC-derived organoids. If this challenge is achieved, these cultures then hold the potential to explain the developmental journey that pluripotent ESCs follow to generate AdSCs that lose their pluripotency but gain tissue-specific self-renewal and multipotency while keeping their ‘adult’ tissue characteristics.
Another question is whether organoids could enable the study of mesenchymal-epithelial interactions in a spatio-temporal manner. We have discussed a recent study, in which mixing human iPSC-derived hepatocytes with MSCs and HUVECS generated an organoid structure that developed into hepatic tissue in vivo upon transplantation (Takebe et al., 2013). Applying such a system to the study of human stem/progenitor cells (PSCs or AdSCs) could provide crucial information as to how human stem cells interact with their endogenous mesenchymal and vascular niches, and address our lack of knowledge on human organ development, maintenance and repair.
Finally, can these systems be used to generate entire transplantable organs in vitro? It has been shown that PSC-derived optic cup organoids developed by self-organization [reviewed by Sasai et al. (2012)] can be engrafted into a mouse model with advanced retinal degeneration and exhibited synaptic connection with the host retina (Assawachananont et al., 2014). The challenge in the field will now be to prove whether these develop into electrophysiologically competent grafts capable of restoring the lost vision upon integration. Nevertheless, this represents the first proof-of-concept that organoids generated in vitro can be used as a transplantable tissue in vivo. It will be interesting to explore whether similar organoid systems, such as the ones described in this Review also result in transplantable organs in the future.
We thank Prof. Takanori Takebe for providing comments on human iPSC-derived liver bud section, Dr Chris Hindley for comments and proof-reading, and Dr Luigi Aloia for help with Fig. 1.
The authors declare no competing or financial interests.
M.H. is a Wellcome Trust Sir Henry Dale Fellow. M.H. is jointly funded by the Wellcome Trust and the Royal Society [104151/Z/14/Z] and receives core support grant from the Wellcome Trust and Cancer Research UK to the Wellcome Trust – Cancer Research UK Gurdon Institute. B.-K.K. is supported by a Sir Henry Dale Fellowship from the Wellcome Trust and the Royal Society [101241/Z/13/Z] and receives core support grant from the Wellcome Trust and MRC to the Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute.
- © 2015. Published by The Company of Biologists Ltd